Gilead Sciences (1GILDM) Stock Overview

A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More details

1GILDM fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	5/6
Past Performance	0/6
Financial Health	3/6
Dividends	4/6

Rewards

Trading at 51.9% below our estimate of its fair value

Earnings are forecast to grow 45.4% per year

Risk Analysis

Shares are highly illiquid

Has a high level of debt

Dividend of 2.19% is not well covered by earnings

1GILDM Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW427,787 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

427,787 investors already sharing narratives

View all narratives

Gilead Sciences, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Gilead Sciences
Historical stock prices
Current Share Price	US$131.07
52 Week High	US$0
52 Week Low	US$0
Beta	0.35
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	1.98%

Recent updates

Shareholder Returns

	1GILDM	GB Biotechs	GB Market
7D	n/a	-0.4%	0.04%
1Y	n/a	-22.2%	15.9%

Return vs Industry: Insufficient data to determine how 1GILDM performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how 1GILDM performed against the UK Market.

Price Volatility

Is 1GILDM's price volatile compared to industry and market?
1GILDM volatility
1GILDM Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.8%
Market Average Movement	4.9%
10% most volatile stocks in GB Market	10.8%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 1GILDM's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine 1GILDM's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1987	17,000	Dan O'Day	www.gilead.com

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients.

Gilead Sciences, Inc. Fundamentals Summary

How do Gilead Sciences's earnings and revenue compare to its market cap?
1GILDM fundamental statistics
Market cap	€162.89b
Earnings (TTM)	-€2.82b
Revenue (TTM)	€26.52b

6.1x

P/S Ratio

-57.4x

P/E Ratio

Is 1GILDM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1GILDM income statement (TTM)
Revenue	US$30.46b
Cost of Revenue	US$6.21b
Gross Profit	US$24.25b
Other Expenses	US$27.49b
Earnings	-US$3.24b

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-2.61
Gross Margin	79.60%
Net Profit Margin	-10.64%
Debt/Equity Ratio	223.5%

How did 1GILDM perform over the long term?

See historical performance and comparison

Dividends

2.2%

Current Dividend Yield

-123%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/18 13:23
End of Day Share Price	2026/09/18 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Gilead Sciences, Inc. is covered by 64 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Toung	Argus Research Company
Brian Skorney	Baird
Emily Field	Barclays

Gilead Sciences, Inc.BATS-CHIXE:1GILDM Stock Report